Reetesh Bose

Reetesh Bose

Auto-generated profile, based on publicly available information

Reetesh Bose

Faculty of Medicine University of Ottawa Ottawa Ontario Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 January 2024 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
OLOwen Dan Luo
Owen Dan Luo
RBReetesh Bose
Reetesh Bose
MBMohammed A. Bawazir
Mohammed A. Bawazir
TTThusanth Thuraisingam
Thusanth Thuraisingam
Feras GhazawiFeras Ghazawi
Feras Ghazawi
Topical photodynamic therapy is a widely approved therapy for actinic keratoses and low-risk nonmelanoma skin cancers with a rapidly growing range of emerging indications for other cutaneous diseases. This review summarizes the best-available evidence to provide a clinical update for dermatologists on the approved and emerging indications of photodynamic therapy. The body of evidence suggests that photodynamic therapy is superior or noninferior to other available treatment modalities for actinic keratoses, low-risk basal cell carcinomas, Bowen’s disease, skin field cancerization, chemoprevention of keratinocyte carcinomas in organ transplant recipients, photoaging, acne vulgaris, and cutaneous infections including verrucae, onychomycosis, and cutaneous leishmaniasis. There is emerging evidence that photodynamic therapy plays a role in the management of actinic cheilitis, early-stage mycosis fungoides, extramammary Paget disease, lichen sclerosis, and folliculitis decalvans but there are no comparative studies with other active treatment modalities. Common barriers to topical photodynamic therapy include procedural pain, costs, and the time required for treatment delivery. There is significant heterogeneity in the photodynamic therapy protocols reported in the literature, including different photosensitizers, light sources, number of treatments, time between treatments, and use of procedural analgesia. Topical photodynamic therapy should be considered in the management of a spectrum of inflammatory, neoplastic, and infectious dermatoses. However, more comparative research is required to determine its role in the treatment algorithm for these dermatologic conditions and more methodological research is required to optimize photodynamic therapy protocols to improve the tolerability of the procedure for patients.

4 October 2023 in JAAD Case Reports
Verified
Journal Article
Open access
MSMysa Saad
Mysa Saad
RBReetesh Bose
Reetesh Bose

20 March 2023 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
LMLinda Mardiros
Linda Mardiros
FMFarhan Mahmood
Farhan Mahmood
SCSophia Colantonio
Sophia Colantonio
RBReetesh Bose
Reetesh Bose
Background: Dermatology for diverse skin types is a globally growing area of medicine, but the inclusion of skin of color dermatology has not yet been formally included across all Canadian undergraduate medical education curricula. There is also a paucity of representation of diverse skin types in most medical textbooks, research, and clinical trials. Objectives: The main objective was to develop a concise, Skin of Colour Dermatoses Self-Learning Module (SOCSLM) that could be implemented at an undergraduate medical education level. The secondary objective was to analyze participant responses to improve and add to learning module content. Methods: From March to May 2022, second-year medical students at the University of Ottawa completed pre- and post-SOCSLM questionnaires which were available in French and English through their online student learning portals. The pre-test consisted of five multiple choice questions relating to images of dermatoses seen in diverse skin types. The post-test repeated the same five questions, rearranged, with an additional five new ones, and responses were analyzed. Results: Twenty-five participants completed the surveys, and twenty responses were included. Percent correct answers increased between pre- and post-test, 51% vs 87%. In the post-test, questions repeated from the pre-test had a mean score of 95% while the new post-test questions had a mean score of 80%. Interest in dermatology did not have an impact on correct response rates. Conclusions: Skin of color dermatology self-learning modules may be an effective way to integrate skin of color dermatology into undergraduate medical curricula.

19 November 2021 in Journal of Cutaneous Medicine and Surgery
Verified
Journal Article
Closed access
PDF file
RBReetesh Bose
Reetesh Bose
SOSelam Ogbalidet
Selam Ogbalidet
MBMina Boshra
Mina Boshra
AFAlexandra Finstad
Alexandra Finstad
BMBarbara Marzario
Barbara Marzario
SFSimone Fahim
Simone Fahim
Background: Cutaneous drug eruptions are a significant source of morbidity, mortality, and cost to the healthcare system. Identifying the culprit drug is essential; however, despite numerous methods being published, there are no consensus guidelines. Objectives: Conduct a scoping review to identify all published methods of culprit drug identification for cutaneous drug eruptions, compare the methods, and generate hypotheses for future causality assessment studies. Eligibility criteria: Peer-reviewed publications involving culprit drug identification methods. Sources of evidence: Medline, Embase, and Cochrane Central Register of Controlled Trials. Charting methods: Registered PRISMA-ScR format protocol on Open Science Forum. Results: In total, 109 studies and 26 reviews were included comprising 656,635 adverse drug events, most of which were cutaneous. There were 54 methods of culprit drug identification published, categorized as algorithms, probabilistic approaches, and expert judgment. Algorithms had higher sensitivity and positive predictive value, but lower specificity and negative predictive value. Probabilistic approaches had lower sensitivity and positive predictive value, but higher specificity and negative predictive value. Expert judgment was subjective, less reproducible, but the most frequently used to validate other methods. Studies suggest that greater accuracy may be achieved by specifically assessing cutaneous drug eruptions and using combinations of causality assessment categories. Conclusions: Culprit drug identification for adverse drug reactions remains a challenge. Many methods have been published, but there are no consensus guidelines. Using causality assessment methods specifically for cutaneous drug eruptions and combining aspects of the different causality assessment categories may improve efficacy. Further studies are needed to validate this hypothesis.

2 August 2025 in Pediatric Dermatology
Verified
Journal Article
Closed access
AKAliyah King
Aliyah King
SSSami G. Sabbah
Sami G. Sabbah
RBReetesh Bose
Reetesh Bose
CHCandrice R. Heath
Candrice R. Heath
NSNanette B. Silverberg
Nanette B. Silverberg

1 January 2024 in Sage Open Medical Case Reports
Verified
Journal Article
Open access
MSMysa Saad
Mysa Saad
MGMarina Guirguis
Marina Guirguis
CHCamille Hamm
Camille Hamm
RBReetesh Bose
Reetesh Bose
Atopic dermatitis is a chronic inflammatory skin disease that may progress to erythroderma in severe cases. Biologic agents such as dupilumab have recently become the mainstay of systemic treatment for moderate-to-severe cases, yet many patients remain refractory to therapy. Here, we present a case of erythrodermic atopic dermatitis, resistant to prednisone and dupilumab, with remarkably rapid achievement of remission following treatment with upadacitinib, an oral selective Janus kinase 1 inhibitor.